Publicaciones (45) Publicaciones de KEPA BELLOSO URIBE

2021

  1. (r)HDL in theranostics: How do we apply HDL's biology for precision medicine in atherosclerosis management?

    Biomaterials Science, Vol. 9, Núm. 9, pp. 3185-3208

  2. A systematic approach to assess the activity and classification of pcsk9 variants

    International Journal of Molecular Sciences, Vol. 22, Núm. 24

  3. Cholesterol stimulates the lytic activity of Adenylate Cyclase Toxin on lipid membranes by promoting toxin oligomerization and formation of pores with a greater effective size

    FEBS Journal, Vol. 288, Núm. 23, pp. 6795-6814

  4. Engineered Repeat Protein Hybrids: The New Horizon for Biologic Medicines and Diagnostic Tools

    Accounts of Chemical Research, Vol. 54, Núm. 22, pp. 4166-4177

  5. In Vivo Evaluation of Multifunctional Gold Nanorods for Boron Neutron Capture and Photothermal Therapies

    ACS Applied Materials and Interfaces, Vol. 13, Núm. 42, pp. 49589-49601

  6. Kukutxeztula: «gainditutako» gaitz baten itzulera

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 39, pp. 61-78

  7. MLb-LDLr: A Machine Learning Model for Predicting the Pathogenicity of LDLr Missense Variants

    JACC: Basic to Translational Science, Vol. 6, Núm. 11, pp. 815-827

  8. Molecular mechanisms of lipotoxicity-induced pancreatic β-cell dysfunction

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 357-402

  9. Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 41, Núm. 2, pp. 934-943

  10. Pre-targeting with ultra-small nanoparticles: Boron carbon dots as drug candidates for boron neutron capture therapy

    Journal of Materials Chemistry B, Vol. 9, Núm. 2, pp. 410-420